Symbols / MREO $0.32 -0.80% Mereo BioPharma Group plc

Healthcare • Biotechnology • United Kingdom • NCM
MREO Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Fundamentals
Scroll to Statements
Market Cap 51.30M Enterprise Value 215.71M Income -41.88M Sales 500.00K Book/sh 0.26 Cash/sh 0.05
Dividend Yield — Payout 0.00% Employees 39 IPO — P/E — Forward P/E -7.98
PEG — P/S 102.60 P/B 1.25 P/C — EV/EBITDA -5.69 EV/Sales 431.43
Quick Ratio 9.99 Current Ratio 10.46 Debt/Eq 0.49 LT Debt/Eq — EPS (ttm) -0.25 EPS next Y -0.04
EPS Growth — Revenue Growth — Earnings 2026-05-12 ROA -39.41% ROE -82.21% ROIC —
Gross Margin 73.40% Oper. Margin -77.11% Profit Margin 0.00% Shs Outstand 159.62M Shs Float 572.33M Short Float 8.40%
Short Ratio 7.65 Short Interest — 52W High 3.05 52W Low 0.20 Beta 0.38 Avg Volume 2.48M
Volume 1.65M Target Price $1.77 Recom None Prev Close $0.32 Price $0.32 Change -0.80%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$1.77
Mean price target
2. Current target
$0.32
Latest analyst target
3. DCF / Fair value
$-2.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.32
Low
$0.50
High
$3.03
Mean
$1.77

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-23 down JP Morgan Overweight → Neutral —
2026-01-16 reit BTIG Buy → Buy $1
2026-01-13 main Needham Buy → Buy $3
2025-12-30 down Jefferies Buy → Hold $1
2025-12-29 main BTIG Buy → Buy $1
2025-12-29 down LifeSci Capital Outperform → Market Perform —
2025-12-22 reit Needham Buy → Buy $5
2025-12-18 reit BTIG Buy → Buy $6
2025-08-25 main JP Morgan Overweight → Overweight $8
2025-07-10 main Needham Buy → Buy $5
2025-05-13 reit Needham Buy → Buy $7
2025-04-09 reit Needham Buy → Buy $7
2025-03-27 init JP Morgan — → Overweight $7
2025-03-26 reit Needham Buy → Buy $7
2025-03-18 reit Cantor Fitzgerald Overweight → Overweight $7
2025-01-13 reit Needham Buy → Buy $7
2024-12-24 init LifeSci Capital — → Outperform $10
2024-12-17 reit Needham Buy → Buy $7
2024-12-06 init Jefferies — → Buy $7
2024-11-12 reit Needham Buy → Buy $7
News
RSS: Latest MREO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-09-13 LEWICKI JOHN A Officer — 16,149 $4.22 $69,477
2024-09-13 SERMON CHARLES E. General Counsel — 30,926 $4.22 $133,051
2024-09-13 SCOTS-KNIGHT DENISE Chief Executive Officer — 88,657 $4.22 $381,423
2024-09-13 HUGHES-WILSON ALEXANDRA Officer — 148,110 $4.22 $637,203
2024-09-13 FOX CHRISTINE ANN Chief Financial Officer — 28,286 $4.22 $121,693
2024-09-11 LEWICKI JOHN A Officer — 46,000 — —
2024-09-11 SERMON CHARLES E. General Counsel — 65,600 — —
2024-09-11 SCOTS-KNIGHT DENISE Chief Executive Officer — 188,060 — —
2024-09-11 HUGHES-WILSON ALEXANDRA Officer — 208,333 $1.01 $206,416
2024-09-11 FOX CHRISTINE ANN Chief Financial Officer — 60,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.50
0.00
-100.00%
10.00
0.00
Operating Revenue
0.50
0.00
-100.00%
10.00
0.00
Cost Of Revenue
0.13
0.00
-100.00%
2.57
+324.61%
-1.15
Reconciled Cost Of Revenue
0.13
0.00
-100.00%
2.57
+324.61%
-1.15
Gross Profit
0.37
0.00
-100.00%
7.43
+547.99%
1.15
Operating Expense
38.62
-15.51%
45.72
+32.27%
34.56
-35.81%
53.84
Research And Development
17.77
-15.12%
20.93
+20.16%
17.42
-40.89%
29.46
Selling General And Administration
23.01
-12.96%
26.43
+43.48%
18.42
-29.43%
26.11
General And Administrative Expense
23.01
-12.96%
26.43
+43.48%
18.42
-29.43%
26.11
Other Gand A
23.01
-12.96%
26.43
+43.48%
18.42
-29.43%
26.11
Other Operating Expenses
-2.15
-30.38%
-1.65
-28.83%
-1.28
+25.93%
-1.73
Total Expenses
38.76
-15.22%
45.72
+23.10%
37.14
-29.53%
52.70
Operating Income
-38.26
+16.31%
-45.72
-68.47%
-27.14
+48.51%
-52.70
Total Operating Income As Reported
-40.11
+15.32%
-47.36
-66.68%
-28.42
+47.79%
-54.43
EBITDA
-40.47
+0.79%
-40.80
-56.57%
-26.06
+31.20%
-37.87
Normalized EBITDA
-34.94
+15.99%
-41.59
-73.61%
-23.95
+51.98%
-49.88
Reconciled Depreciation
1.15
+5.61%
1.09
+2.54%
1.06
+19.35%
0.89
EBIT
-41.62
+0.62%
-41.88
-54.45%
-27.12
+30.04%
-38.76
Total Unusual Items
-5.54
-800.25%
0.79
+137.63%
-2.10
-117.50%
12.01
Total Unusual Items Excluding Goodwill
-5.54
-800.25%
0.79
+137.63%
-2.10
-117.50%
12.01
Special Income Charges
—
—
—
0.00
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
-41.88
+3.18%
-43.25
-46.79%
-29.47
+30.21%
-42.22
Pretax Income
-41.88
+3.18%
-43.25
-44.19%
-30.00
+30.14%
-42.94
Net Non Operating Interest Income Expense
1.92
+14.78%
1.67
+322.80%
-0.75
+77.51%
-3.33
Interest Expense Non Operating
0.26
-81.39%
1.37
-52.45%
2.88
-30.99%
4.17
Net Interest Income
1.92
+14.78%
1.67
+322.80%
-0.75
+77.51%
-3.33
Interest Expense
0.26
-81.39%
1.37
-52.45%
2.88
-30.99%
4.17
Interest Income Non Operating
2.17
-28.54%
3.04
+42.70%
2.13
+153.69%
0.84
Interest Income
2.17
-28.54%
3.04
+42.70%
2.13
+153.69%
0.84
Other Income Expense
-5.54
-800.25%
0.79
+137.45%
-2.11
-116.13%
13.10
Other Non Operating Income Expenses
—
—
-0.01
-100.92%
1.09
Gain On Sale Of Security
-5.54
-800.25%
0.79
+137.63%
-2.10
-117.50%
12.01
Tax Provision
0.00
0.00
+100.00%
-0.53
+25.91%
-0.72
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+7.64%
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-0.04
-118.84%
0.20
Net Income Including Noncontrolling Interests
-41.88
+3.18%
-43.25
-46.79%
-29.47
+30.21%
-42.22
Net Income From Continuing Operation Net Minority Interest
-41.88
+3.18%
-43.25
-46.79%
-29.47
+30.21%
-42.22
Net Income From Continuing And Discontinued Operation
-41.88
+3.18%
-43.25
-46.79%
-29.47
+30.21%
-42.22
Net Income Continuous Operations
-41.88
+3.18%
-43.25
-46.79%
-29.47
+30.21%
-42.22
Normalized Income
-36.34
+17.49%
-44.04
-60.73%
-27.40
+49.28%
-54.03
Net Income Common Stockholders
-41.88
+3.18%
-43.25
-46.79%
-29.47
+30.21%
-42.22
Diluted EPS
-0.25
+16.67%
-0.30
-50.00%
-0.20
+44.91%
-0.36
Basic EPS
-0.25
+16.67%
-0.30
-50.00%
-0.20
+44.91%
-0.36
Basic Average Shares
159.42
+7.77%
147.92
+12.16%
131.89
+15.71%
113.99
Diluted Average Shares
159.42
+7.77%
147.92
+12.16%
131.89
+15.71%
113.99
Diluted NI Availto Com Stockholders
-41.88
+3.18%
-43.25
-46.79%
-29.47
+30.21%
-42.22
Average Dilution Earnings
—
—
—
0.00
Gain On Sale Of PPE
—
—
—
0.00
Total Other Finance Cost
—
—
—
0.05
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
66.50
-14.10%
77.41
—
Current Assets
63.76
-15.21%
75.20
—
Cash Cash Equivalents And Short Term Investments
57.42
-15.78%
68.18
—
Cash And Cash Equivalents
57.42
-15.78%
68.18
—
Cash Equivalents
—
51.10
+6554.66%
0.77
Cash Financial
—
5.23
-95.87%
126.50
Receivables
3.73
+35.81%
2.75
—
Other Receivables
3.13
+99.68%
1.57
—
Taxes Receivable
0.60
-49.19%
1.18
—
Prepaid Assets
2.27
-19.98%
2.83
—
Other Current Assets
0.34
-76.29%
1.43
—
Total Non Current Assets
2.74
+23.60%
2.22
—
Net PPE
1.65
-25.54%
2.22
—
Gross PPE
2.45
-17.01%
2.95
—
Accumulated Depreciation
-0.80
-8.70%
-0.74
—
Properties
0.00
0.00
—
Buildings And Improvements
1.25
-25.23%
1.67
—
Machinery Furniture Equipment
0.20
+4.74%
0.19
—
Other Properties
0.30
-29.86%
0.42
—
Leases
0.71
+5.19%
0.68
—
Goodwill And Other Intangible Assets
1.09
0.00
—
Other Intangible Assets
1.09
-95.48%
24.12
-27.26%
33.15
Total Liabilities Net Minority Interest
15.96
-38.63%
26.01
—
Current Liabilities
9.49
-61.08%
24.38
—
Payables And Accrued Expenses
6.47
-10.98%
7.27
—
Payables
3.01
-18.57%
3.69
—
Accounts Payable
2.35
-32.82%
3.49
—
Other Payable
—
0.03
-22.82%
0.03
Current Accrued Expenses
3.46
-3.13%
3.57
—
Pensionand Other Post Retirement Benefit Plans Current
1.62
-12.83%
1.86
—
Total Tax Payable
0.66
+227.72%
0.20
—
Current Debt And Capital Lease Obligation
0.65
-95.31%
13.89
—
Current Debt
—
13.33
—
Other Current Borrowings
—
13.33
—
Current Capital Lease Obligation
0.65
+15.60%
0.56
—
Current Deferred Liabilities
0.71
0.00
—
Other Current Liabilities
0.03
-97.79%
1.35
—
Total Non Current Liabilities Net Minority Interest
6.48
+295.84%
1.64
—
Long Term Debt And Capital Lease Obligation
5.30
+258.35%
1.48
—
Long Term Debt
4.39
—
19.41
Long Term Capital Lease Obligation
0.91
-38.74%
1.48
—
Long Term Provisions
—
—
1.78
Other Non Current Liabilities
0.76
+319.78%
0.18
—
Stockholders Equity
50.54
-1.68%
51.40
—
Common Stock Equity
50.54
-1.68%
51.40
—
Capital Stock
2.77
+11.99%
2.48
—
Common Stock
2.77
+11.99%
2.48
—
Share Issued
701.22
+12.21%
624.93
—
Ordinary Shares Number
700.29
+12.24%
623.93
—
Treasury Shares Number
0.92
-7.94%
1.00
-7.23%
1.08
Additional Paid In Capital
486.11
+2.01%
476.52
—
Retained Earnings
-419.63
-3.72%
-404.57
—
Gains Losses Not Affecting Retained Earnings
-17.48
+19.38%
-21.69
—
Treasury Stock
1.23
-7.87%
1.33
-13.23%
1.54
Other Equity Adjustments
-17.48
+19.38%
-21.69
—
Total Equity Gross Minority Interest
50.54
-1.68%
51.40
—
Total Capitalization
54.93
+6.87%
51.40
—
Working Capital
54.27
+6.79%
50.82
—
Invested Capital
54.93
-15.14%
64.73
—
Total Debt
5.95
-61.27%
15.37
—
Capital Lease Obligations
1.56
-23.74%
2.04
—
Net Tangible Assets
49.45
-3.80%
51.40
—
Tangible Book Value
49.45
-3.80%
51.40
—
Current Provisions
—
4.82
+27.46%
3.78
Derivative Product Liabilities
0.41
+162.42%
0.16
—
Foreign Currency Translation Adjustments
—
-2.17
-371.29%
-0.46
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-30.97
+5.67%
-32.83
-55.38%
-21.13
+56.72%
-48.82
Cash Flow From Continuing Operating Activities
-30.97
+5.67%
-32.83
-55.38%
-21.13
+56.72%
-48.82
Net Income From Continuing Operations
-41.88
+3.18%
-43.25
-46.79%
-29.47
+30.21%
-42.22
Depreciation Amortization Depletion
1.15
+5.61%
1.09
+2.54%
1.06
+19.35%
0.89
Depreciation
0.68
+5.23%
0.65
-2.40%
0.67
-25.08%
0.89
Amortization Cash Flow
0.47
+6.16%
0.44
+10.89%
0.40
0.00
Depreciation And Amortization
1.15
+5.61%
1.09
+2.54%
1.06
+19.35%
0.89
Amortization Of Intangibles
0.47
+6.16%
0.44
+10.89%
0.40
0.00
Other Non Cash Items
-0.07
-102.32%
3.10
+68.53%
1.84
-12.51%
2.10
Stock Based Compensation
7.60
+2.81%
7.39
+50.08%
4.92
+3.27%
4.77
Provisionand Write Offof Assets
—
—
—
0.26
Asset Impairment Charge
—
—
—
—
Operating Gains Losses
5.43
+787.10%
-0.79
-137.63%
2.10
+117.50%
-12.01
Gain Loss On Investment Securities
-0.91
-316.95%
0.42
+271.02%
-0.24
+97.36%
-9.29
Net Foreign Currency Exchange Gain Loss
6.34
+624.30%
-1.21
-151.56%
2.35
+186.19%
-2.72
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
-3.20
-768.02%
-0.37
+76.84%
-1.59
+32.27%
-2.35
Change In Receivables
1.40
+184.66%
-1.65
-461.62%
0.46
+113.15%
-3.47
Change In Prepaid Assets
-0.08
-102.82%
2.98
+493.63%
0.50
-5.64%
0.53
Change In Payables And Accrued Expense
-3.77
-260.61%
-1.05
+46.98%
-1.97
-235.04%
1.46
Change In Accrued Expense
-2.39
-100.84%
-1.19
-67.89%
-0.71
-184.12%
0.84
Change In Payable
-1.38
-1043.84%
0.15
+111.56%
-1.26
-304.70%
0.62
Change In Account Payable
-1.38
-1043.84%
0.15
+111.56%
-1.26
-304.70%
0.62
Change In Other Current Liabilities
-0.74
-13.61%
-0.65
-13.15%
-0.58
+34.17%
-0.88
Investing Cash Flow
-0.02
+97.14%
-0.70
-66.83%
-0.42
-121.09%
1.99
Cash Flow From Continuing Investing Activities
-0.02
+97.14%
-0.70
-66.83%
-0.42
-121.09%
1.99
Net PPE Purchase And Sale
-0.02
0.00
0.00
-100.00%
1.99
Purchase Of PPE
-0.02
0.00
0.00
+100.00%
-0.01
Sale Of PPE
—
—
0.00
-100.00%
2.00
Capital Expenditure
-0.32
+54.22%
-0.70
-66.83%
-0.42
-3123.08%
-0.01
Net Investment Purchase And Sale
—
—
—
—
Sale Of Investment
—
—
—
—
Net Business Purchase And Sale
—
—
—
0.00
Purchase Of Business
—
—
—
0.00
Net Intangibles Purchase And Sale
-0.30
+57.08%
-0.70
-66.83%
-0.42
0.00
Purchase Of Intangibles
-0.30
+57.08%
-0.70
-66.83%
-0.42
0.00
Net Other Investing Changes
0.30
—
—
-0.81
Financing Cash Flow
0.33
-99.29%
46.15
+478.79%
7.97
+3886.50%
0.20
Cash Flow From Continuing Financing Activities
0.33
-99.29%
46.15
+478.79%
7.97
+3886.50%
0.20
Net Issuance Payments Of Debt
—
0.00
+100.00%
-3.19
-181.14%
-1.13
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
0.00
+100.00%
-3.19
-181.14%
-1.13
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
0.00
+100.00%
-3.19
-181.14%
-1.13
Net Long Term Debt Issuance
—
0.00
+100.00%
-3.19
-181.14%
-1.13
Net Common Stock Issuance
0.04
-99.92%
47.00
+305.00%
11.61
0.00
Common Stock Payments
—
—
—
—
Cash Dividends Paid
—
—
—
0.00
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
0.49
0.00
—
0.00
Net Other Financing Charges
-0.20
+76.67%
-0.85
-92.12%
-0.44
-322.00%
0.20
Changes In Cash
-30.66
-343.09%
12.61
+192.89%
-13.58
+70.88%
-46.63
Effect Of Exchange Rate Changes
1.85
+895.71%
-0.23
-108.27%
2.82
+122.40%
-12.58
Beginning Cash Position
69.80
+21.56%
57.42
-15.78%
68.18
-46.48%
127.40
End Cash Position
40.99
-41.27%
69.80
+21.56%
57.42
-15.78%
68.18
Free Cash Flow
-31.29
+6.69%
-33.53
-55.60%
-21.55
+55.87%
-48.83
Interest Paid Supplemental Data
0.03
+38.10%
0.02
-97.62%
0.88
—
Income Tax Paid Supplemental Data
—
0.00
—
—
Common Stock Issuance
0.04
-99.92%
47.00
+305.00%
11.61
0.00
Interest Paid CFF
—
—
—
0.00
Interest Received CFI
—
—
—
0.84
Issuance Of Capital Stock
0.04
-99.92%
47.00
+305.00%
11.61
0.00
Sale Of Business
—
—
—
—
Sale Of Intangibles
—
—
—
1.80
Taxes Refund Paid
—
—
—
-1.85
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category